Eversept Partners, LP Otonomy, Inc. Transaction History

Eversept Partners, LP

  • $1.26 Billion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 13, 2021
SELL
$2.49 - $6.23 $630,674 - $1.58 Million
-253,283 Closed
0 $0
Q4 2020

Nov 08, 2023
BUY
$3.48 - $6.47 $881,424 - $1.64 Million
253,283 New
253,283 $1.64 Million
Q4 2020

Feb 16, 2021
SELL
$3.48 - $6.47 $554,075 - $1.03 Million
-159,217 Reduced 38.6%
253,283 $1.64 Million
Q3 2020

Nov 08, 2023
SELL
$3.16 - $4.36 $596,175 - $822,570
-188,663 Reduced 31.38%
412,500 $1.67 Million
Q3 2020

Nov 13, 2020
SELL
$3.16 - $4.36 $596,175 - $822,570
-188,663 Reduced 31.38%
412,500 $1.67 Million
Q2 2020

Nov 08, 2023
BUY
$1.87 - $3.84 $73,726 - $151,395
39,426 Added 7.02%
601,163 $2.18 Million
Q2 2020

Aug 13, 2020
BUY
$1.87 - $3.84 $73,726 - $151,395
39,426 Added 7.02%
601,163 $2.18 Million
Q1 2020

Nov 08, 2023
BUY
$1.58 - $4.06 $17,493 - $44,952
11,072 Added 2.01%
561,737 $1.11 Million
Q1 2020

May 13, 2020
BUY
$1.58 - $4.06 $17,493 - $44,952
11,072 Added 2.01%
561,737 $1.11 Million
Q4 2019

Nov 08, 2023
BUY
$2.13 - $3.83 $371,307 - $667,657
174,323 Added 46.32%
550,665 $2.11 Million
Q4 2019

Feb 13, 2020
BUY
$2.13 - $3.83 $371,307 - $667,657
174,323 Added 46.32%
550,665 $2.11 Million
Q3 2019

Nov 08, 2023
BUY
$2.12 - $2.86 $385,655 - $520,271
181,913 Added 93.56%
376,342 $899,000
Q3 2019

Nov 13, 2019
BUY
$2.12 - $2.86 $385,655 - $520,271
181,913 Added 93.56%
376,342 $899,000
Q2 2019

Nov 08, 2023
BUY
$2.35 - $3.09 $33,673 - $44,276
14,329 Added 7.96%
194,429 $534,000
Q2 2019

Aug 13, 2019
BUY
$2.35 - $3.09 $33,673 - $44,276
14,329 Added 7.96%
194,429 $535,000
Q1 2019

Nov 08, 2023
BUY
$1.8 - $2.97 $324,180 - $534,897
180,100 New
180,100 $473,000
Q1 2019

May 14, 2019
BUY
$1.8 - $2.97 $324,180 - $534,897
180,100 New
180,100 $474,000

About OTONOMY, INC.

OTIC Quotes by TradingView
  • Ticker OTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,990,400
  • Description
  • Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...
More about OTIC
Track This Portfolio

Track Eversept Partners, LP Portfolio

Follow Eversept Partners, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email